Relevant bibliographies by topics / North American Vaccine Inc

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'North American Vaccine Inc'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'North American Vaccine Inc.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "North American Vaccine Inc"

1

Thomas, Sheeba K., Soung-chul Cha, Sapna R. Parshottam, Sheetal S. Rao, Jasper B. Olsem, Brandon N. Crumpton, Szymon Szymura, et al. "A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM)." Blood 136, Supplement 1 (November 5, 2020): 6–7. http://dx.doi.org/10.1182/blood-2020-140007.

Full text
Abstract:
Background: Idiotypic determinants of the surface immunoglobulin (Ig) associated with a given pt's B-cell lymphoma are unique to that tumor, and can thus serve as a tumor-specific marker. This study aims to use an idiotype DNA vaccine to lengthen the smoldering phase of WM without inducing cross-resistance to available therapies. Administered vaccine used recombinant plasmid DNA encoding a fusion protein, consisting of autologous lymphoma scFv (pt-specific idiotype) and human CCL20 (macrophage inflammatory protein-3 alpha - MIP-3α) chemokine. Targeted delivery of this fusion protein to antigen-presenting cells, and subsequent processing and presentation, is hypothesized to break tolerance and generate an immune response against the idiotype, promoting eradication of antigen-expressing B-cell lymphoma cells. Methods: Pts with sWM received 3 intradermal vaccinations of pt-specific DNA vaccine at 4-week (wk) intervals (wks 0, 4 and 8). Two dose levels (500 µg; 2500 µg) were evaluated in a 3+3 design. The primary objective was to evaluate the vaccine's safety and identify the maximum tolerated dose. Secondary objectives were to assess immunogenicity of the vaccine to generate tumor-specific cellular immune responses. Results: Between 1/2016 - 1/2019, 9 pts (7 men) were treated (500 µg: n = 3; 2500 µg: n = 6). Median age at enrollment was 67 yrs (range 56-78); median time from diagnosis to 1st vaccination was 26.5 mos (8.8-120.9). MYD88 L265P + (6 pts). CXCR4 WHIM + (1 pt). With median follow up of 38 months (range: 8.8-51), 8 pts are known alive; 1 has been lost to follow up. Six have maintained stable disease; 3 have progressed to symptomatic WM at 8, 25, and 28 months respectively, from 1st vaccination). All pts completed planned therapy. No DLTs or Grade 4 AEs occurred. Ten mos. after the 3rd vaccination, 1 pt had a grade 3 pleural effusion and leukopenia with an increase in rheumatoid factor (23.1 IU/mL [normal range 0.0-15.9]) and ANA titer of 1:80; all resolved within 2 mos. Grade 1-2 AEs observed in > 3pts include: leukopenia (6), nausea (5), anemia (4), increased creatinine (4), fatigue (4). Immune correlatives have now been completed in all 9 patients. Analysis is ongoing, and complete data will be presented at the meeting. Serial pre- and post- vaccine samples analyzed by single-cell RNA seq from 3 representative patients (LPL 005, LPL 007, LPL 008) treated at the 2500 mg dose are shown in the Figure. DNA vaccine treatment significantly reduced the number of clonal B-cells in the bone marrow compartment of the 2 patients who have maintained SD (LPL 007 and LPL 008). DNA vaccine treatment also induced increases in monocytes in the tumor microenvironment of these 2 patients. In addition, T-cell receptor (TCR) sequence analysis revealed clear increases in TCR clonal expansions, consistent with a vaccine effect. In contrast, LPL 005, who had the earliest progression to symptomatic phase WM, had an increase in tumor B cells on post vaccine samples, and TCR clonotypes showed no changes. Similar changes were observed with serial bone marrow samples from the remaining patients treated on the trial, correlating with clinical outcome. Conclusions: Idiotype (scFv-CCL20) DNA vaccine therapy appears to be safe in pts with sWM. Preliminary results of serial single cell RNAseq analysis suggest that the tumor immune microenvironment is favorably altered after chemokine-tumor antigen DNA vaccine treatment and these vaccine-induced changes may correlate with clinical outcome. The immunologic changes observed suggest response to this vaccine, and warrant further investigation in a Phase II trial, possibly in combination with immune checkpoint blockade. Disclosures Thomas: Ascentage: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Genentech: Research Funding; Pharmacyclics: Other: Advisory Boards; Xencor: Research Funding; X4 Pharma: Research Funding. Lee:GlaxoSmithKline: Consultancy, Research Funding; Regeneron: Research Funding; Daiichi Sankyo: Research Funding; Amgen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Genentech: Consultancy; Sanofi: Consultancy; Genentech: Consultancy. Manasanch:Adaptive Biotechnologies: Honoraria; Glaxo Smith Kline: Honoraria; BMS: Honoraria; Takeda: Honoraria; Quest Diagnostics: Research Funding; Merck: Research Funding; JW Pharma: Research Funding; Novartis: Research Funding; Sanofi: Honoraria, Research Funding. Patel:Nektar: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Precision Biosciences: Research Funding; Celgene: Consultancy, Research Funding; Cellectis: Research Funding; Poseida: Research Funding; Oncopeptides: Consultancy. Orlowski:Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current submission.: Current equity holder in private company, Patents & Royalties; Laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc.: Research Funding; STATinMED Research: Consultancy; Sanofi-Aventis, Servier, Takeda Pharmaceuticals North America, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen, Inc., AstraZeneca, BMS, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc.,: Honoraria, Membership on an entity's Board of Directors or advisory committees. Neelapu:Takeda Pharmaceuticals: Patents & Royalties; Bristol-Myers Squibb: Other: personal fees, Research Funding; Merck: Other: personal fees, Research Funding; Kite, a Gilead Company: Other: personal fees, Research Funding; N/A: Other; Acerta: Research Funding; Karus Therapeutics: Research Funding; Cellectis: Research Funding; Poseida: Research Funding; Unum Therapeutics: Other, Research Funding; Calibr: Other; Adicet Bio: Other; Legend Biotech: Other; Allogene Therapeutics: Other: personal fees, Research Funding; Cell Medica/Kuur: Other: personal fees; Incyte: Other: personal fees; Precision Biosciences: Other: personal fees, Research Funding; Celgene: Other: personal fees, Research Funding; Novartis: Other: personal fees; Pfizer: Other: personal fees. Kwak:CJ Healthcare: Consultancy; Sellas Life Sciences Grp: Consultancy; Enzychem Life Sciences: Membership on an entity's Board of Directors or advisory committees; Antigenics: Other: equity; InnoLifes, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pepromene Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Xeme Biopharma/Theratest: Other: equity; Celltrion Healthcare: Membership on an entity's Board of Directors or advisory committees; Celltrion, Inc.: Consultancy. OffLabel Disclosure: This study aims to use a novel idiotype DNA vaccine to lengthen the smoldering phase of WM without inducing cross-resistance to available therapies.
APA, Harvard, Vancouver, ISO, and other styles
2

LOWNDES, C. M. "Vaccines for cervical cancer." Epidemiology and Infection 134, no. 1 (January 12, 2006): 1–12. http://dx.doi.org/10.1017/s0950268805005728.

Full text
Abstract:
SUMMARYThis review focuses on current and future prevention of invasive cervical cancer (ICC), the second most common cancer among women worldwide. Implementation of population-based cytological screening programmes, using the ‘Pap’ smear to detect pre-cancerous lesions in the cervix, has resulted in substantial declines in mortality and morbidity from ICC in North America and some European countries. However, cases of, and deaths from, ICC continue to occur. Primary prevention of infection with high-risk human papillomavirus (HPV) types, the central causal factor of ICC, could further reduce incidence of and mortality from ICC. This is particularly the case in developing countries, which bear 80% of the burden of ICC, and where effective Pap screening programmes are extremely difficult to implement. Very promising results from several trials of synthetic HPV type-specific monovalent (HPV 16) and bivalent (HPV 16 and 18) vaccines have recently been published, showing high efficacy against type-specific persistent HPV infection and development of type-specific pre-cancerous lesions. Large-scale phase III trials of a number of such vaccine candidates are currently underway, and there is real hope that an effective vaccine capable of protecting against infection with HPV types 16 and 18 (which together account for ∼70% of cervical cancer cases worldwide), and thereby of preventing development of a very significant proportion of cases of ICC, could be available within the next 2 years.
APA, Harvard, Vancouver, ISO, and other styles
3

Volkening, Tom. "North American Fruit Explorers, Inc. (NAFEX) http://www.nafex.org." Journal of Agricultural & Food Information 5, no. 4 (October 4, 2003): 5–13. http://dx.doi.org/10.1300/j108v05n04_03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zink, Robert M. "North American/World BirdArea and BirdBase Santa Barbara Software Products, Inc." Auk 114, no. 1 (January 1997): 157–58. http://dx.doi.org/10.2307/4089091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hamilton, K. G. A. "THE SPECIES OF THE NORTH AMERICAN LEAFHOPPERSCERATAGALLIAKIRKALDY ANDACERATAGALLIAKIRKALDY (RHYNCHOTA: HOMOPTERA: CICADELLIDAE)." Canadian Entomologist 130, no. 4 (August 1998): 427–90. http://dx.doi.org/10.4039/ent130427-4.

Full text
Abstract:
AbstractThe North American genusCeratagalliaKirkaldy, 1907 is redefined to include subgenusAceratagalliaKirkaldy, 1907 (=IoniaBall, 1933, syn.nov.) with 78 species in two subgenera. Two additional new species are unplaced to subgenus:C. aceratafrom Oregon, andC. emarginatafrom Mexico. The typical subgenusCeratagalliahas 30 species, includingC. gillettei(Osborn & Ball, comb.nov.),C. sordida(Oman, comb.nov.), and two new speciesC. anafrom Mexico andC. viperafrom Washington state. SubgenusAceratagalliahas 46 species, all new combinations underCeratagallia. The economic "species" formerly known as "sanguinolenta" is divided into the Canadian clover leafhopperC. humilis(Oman) and the American clover leafhopperC. agricolasp.nov. Other new taxa in subgenusAceratagalliainclude 18 new species and seven new subspecies:alaskana(ssp. ofsiccifolia)from Alaska;omanion the Pacific coast from Oregon to British Columbia;clinoandlophiafrom the Oregon interior;compressa(ssp. ofsiccifolia),gallus,modesta,okanagana, andzacki(ssp. ofnanella) from intermontane valleys of the Pacific northwest and southwestern mountains;interior(ssp. ofhumilis) androssifrom the Sonoran subregion;australis(ssp. ofnanella),coma,ebena,entoma,falcata,oionus, andvenosafrom Mexico and Texas;alvarana(ssp. ofhumilis),cerea,cristula,harrisi, semiarida, andviatorwidespread between the Appalachian and Rocky Mountains; andwhitcombi(ssp. ofrobusta) from Florida to Arizona. Four former species are reduced to subspecies:compactaOman andpoudrisOman inC. robusta(Oman),helveolaOman inC. cinerea(Osborn & Ball), andtruncataOman inC. humilis. The taxa are keyed and illustrated, and their phylogeny is discussed.
APA, Harvard, Vancouver, ISO, and other styles
6

Cramer, Michael D. "A changing world: proceedings of the North American serials interest group, inc." Library Acquisitions: Practice & Theory 17, no. 3 (September 1993): 392–93. http://dx.doi.org/10.1016/0364-6408(93)90094-m.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Heron, Iver, F. M. Chen, and Joan Fusco. "DTaP Vaccines from North American Vaccine (NAVA): Composition and Critical Parameters." Biologicals 27, no. 2 (June 1999): 91–96. http://dx.doi.org/10.1006/biol.1999.0187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marshall, Mazepa A., Michael Evans, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan R. Woods, et al. "Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations." Blood 134, Supplement_1 (November 13, 2019): 90. http://dx.doi.org/10.1182/blood-2019-129383.

Full text
Abstract:
Introduction The United States Thrombotic Microangiopathy (USTMA) Consortium consists of high-volume US referral centers that are committed to collaborative research in TMAs. The USTMA Immune Thrombotic Thrombocytopenic Purpura (iTTP) registry has compiled retrospective data on demographics, treatments and outcomes in patients with iTTP to create the world's largest database of patients with this rare disease. While there is consensus on the use of therapeutic plasma exchange (TPE) for treatment of iTTP, there are no large randomized trials on which to base use of rituximab. The drug is frequently used for refractory or relapsed iTTP, but is currently being used more frequently for de novo (first episode) iTTP. We queried the USTMA iTTP registry to determine whether relapse free survival (RFS) is superior when rituximab is added to TPE and corticosteroids for treatment of iTTP. We hypothesized that the addition of rituximab would improve RFS at 5 years in both de novo and relapsing iTTP. Methods Following IRB approval at each institution, investigators independently reviewed individual patient records to confirm diagnostic criteria and entered demographic, treatment and outcomes data into the REDCap database housed at the University of North Carolina. The diagnosis of iTTP was defined as ADAMTS13 < 10% or ADAMTS13 < 20% with an inhibitor or antibody detected at any point or a clinical diagnosis of iTTP based on presenting characteristics, response to treatment and/or relapsing phenotype before ADAMTS13 testing became available (N=173). Relapse was defined as a recurrence of iTTP after at least 30 days of remission (recurrence within 30 days was considered an exacerbation, or continuation of the prior episode). To explore the effect of rituximab added to TPE and corticosteroids, we first assessed the treatment effect in de novo iTTP patients and then separately in relapse. We constructed Kaplan-Meier curves to compare RFS for patients treated with rituximab plus corticosteroids versus corticosteroids alone in both groups, and compared RFS at specific time points using the Klein method. To better understand whether other patient variables had an effect on RFS in both de novo episodes and relapses, ordinary (time-to-event) and mixed-effects (recurrent time-to-event) Cox proportional hazards models were used to examine the relationships of treatment, race/ethnicity, sex, age, treatment year, and presenting signs/symptoms with the outcome. Analyses were conducted using R version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). Results As of July, 2019, the USTMA database contains 775 unique study patients with a confirmed diagnosis of iTTP with 1397 unique iTTP episodes. The treatment of patients' de novo iTTP episode was available for analysis in 375 patients, 188 of whom were treated with corticosteroids alone, 131 with corticosteroids plus rituximab, and 56 with other therapies. RFS was significantly higher in patients treated with corticosteroids and rituximab compared to those treated with corticosteroids alone at 1 year (0.93 vs. 0.78, p=0.0002) and 3 years (0.82 vs. 0.66, p=0.004) but not 5 years (0.60 vs. 0.56, p=0.39). In addition, the risk of relapse decreased with later treatment year for de novo iTTP (hazard ratio (HR) 0.95, 95% CI 0.92-0.99, p=0.03), consistent with rituximab use increasing over time, and was increased in African Americans compared with Caucasians (HR 1.83, 1.10-3.06, p=0.02). We then explored the treatment effect in all iTTP relapses (743 relapses in 426 patients). Here, a significant (p=0.0007) interaction between treatment and race was found. Among African Americans, we found no difference in RFS when rituximab was added (HR 1.15, 0.81-1.62, p=0.43). However, among Caucasians, RFS was significantly improved when rituximab was added (HR 0.15, 0.06-0.35, p<0.0001). Conclusions For de novo iTTP, adding rituximab to corticosteroids for immunosuppression likely delays but does not prevent relapse. Unlike in de novo disease, in patients with relapsed iTTP, we found a novel and significant interaction between race and treatment: while Caucasians had significantly improved RFS with the addition of rituximab, there was no effect on RFS in African Americans. Further investigation is warranted to determine the mechanisms of this difference in the response to rituximab in relapsed iTTP to improve outcomes in African Americans. Figure Disclosures Marshall: Sanofi: Membership on an entity's Board of Directors or advisory committees. Farland:Sanofi: Membership on an entity's Board of Directors or advisory committees. Metjian:Sanofi: Membership on an entity's Board of Directors or advisory committees. Raval:Bayer, Inc: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees. Liles:Imara: Other: PI on Clinical trial- Sickle cell ; Shire: Other: PI on clinical trial Sickle cell ; Novartis: Other: PI on clinical trial Sickle cell . Baumann Kreuziger:CSL Behring: Consultancy; Vaccine Injury Compensation Program: Consultancy. McCrae:Rigel Pharmaceutical: Membership on an entity's Board of Directors or advisory committees; Sanofi Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Dova Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Pfizer Pharmaceutical: Membership on an entity's Board of Directors or advisory committees. Chaturvedi:Shire/Takeda: Research Funding; Sanofi: Consultancy; Alexion: Consultancy. Zheng:Clotsolution: Other: Co-Founder; Shire/Takeda: Research Funding; Ablynx/Sanofi: Consultancy, Speakers Bureau; Alexion: Speakers Bureau. Cataland:Ablynx/Sanofi: Consultancy, Research Funding; Alexion: Consultancy, Research Funding. Off Label Disclosure: rituximab for immunosuppression in TTP.
APA, Harvard, Vancouver, ISO, and other styles
9

Clark, Cynthia D. "New Scholarship: New Serials: Proceedings of the North American Serials Interest Group, Inc." Serials Review 21, no. 2 (June 1995): 101–3. http://dx.doi.org/10.1080/00987913.1995.10764255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Davis, Susan. "The future of serials: Proceedings of the North American Serials Interest Group, Inc." Library Acquisitions: Practice & Theory 16, no. 3 (September 1992): 331–32. http://dx.doi.org/10.1016/0364-6408(92)90050-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "North American Vaccine Inc"

1

Liao, Hui Ren, and 廖惠仁. "Zesso Electronics, Inc - Business Plan for the Distribution of North American and European Industrial Products in Asia." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/g7ft46.

Full text
Abstract:
碩士
國立政治大學
國際經營管理英語碩士學位學程(IMBA)
104
Since the mid 1990’s, the world manufacturing had being shifting to Asia especially in China. In 1990, Asia produces less than 10% of global manufacturing output by value, Today around 70% of the world’s air-conditioners, 70% of its mobile phones and 60% of its shoes are manufactured in Asia. Electronic equipments manufacturers for reliable power and physical IT infrastructure had their main manufacturing units in Asia, mostly in India, China, Taiwan and the Philippines. Various electronic components are required for the manufacturing of these power related equipments. It is known that Arrow-Hart Electric, Inc. (USA) and CD Electric (Austria) is recently seeking for distributors in the Asian territory, and that Asia is still an open market. A business plan should be submitted to both Arrow-Hart Electric, Inc. (USA) and CD Electric (Austria) to become a distributor of their products. We also learned that the distributor should submit 3% of the total gross margin as royalty, in return for the sole distribution right (exclusive distributorship). Royalty fees to be paid-out every middle and end of the fiscal year. For the above purpose, Zesso Electronics, Inc will be established, seeking to become the sole distributor of Arrow-Hart Electric, Inc and CD Electric for Asia-Pacific region. Upon appointment, the company will market, sell and distribute the products branded by Arrow-Hart Electric, Inc and CD Electric. Zesso Electronics, Inc will become the first to formally represent Arrow-Hart Electric brands and CD Electric for the Asia-Pacific region, participating in well known trade exhibitions in Asia and promoting its products.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "North American Vaccine Inc"

1

Patrick, Robert L. General Motors/North American Monitor for the IBM 704 computer. Santa Monica, CA: Rand, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Trotter, Claude Russell. A spendid enterprise: History of the General Baptist State Convention of North Carolina, Inc. Raleigh, NC: Irving-Swain Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Horkey, Edward J. The real stuff. Los Olivos, CA: Olive Press Publications, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Disease and class: Tuberculosis and the shaping of modern North American society. New Brunswick, N.J: Rutgers University Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Feldberg, Georgina D. Disease and class: Tuberculosis and the shaping of modern North American society. New Brunswick, N.J: Rutgers University Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Conference, North American Serials Interest Group. A kaleidoscope of choices: Reshaping roles and opportunities for serialists : proceedings of the North American Serials Interest Group, Inc. New York: Haworth Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

School), Harvard Indian Law Symposium (1989 Harvard Law. 1989 Harvard Indian Law Symposium: Papers published in conjunction with a conference presented by the Harvard Chapter of the American Indian Law Students Association, co-sponsored by the National American Indian Law Students Association, Inc., and the American Indian Bar Association. [Cambridge, MA: Harvard Law School Publications Center], 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

North American Serials Interest Group (6th 1991 Trinity University, San Antonio, Texas). A changing world: Proceedings of the North American Serials Interest Group, Inc., 6th Annual Conference, June 14-17, 1991, Trinity University, San Antonio, Texas. Edited by McMahon Suzanne, Palm Miriam, and Dunn Pam. New York: Haworth Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

North American Serials Interest Group. (8th 1993 Brown University). New scholarship--new serials: Proceedings of the North American Serials Interest Group, Inc., 8th Annual Conference, June 10-13, 1993, Brown University, Providence, R.I. Edited by McMillan Gail and Norstedt Marilyn. New York: Haworth Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ohl, Rice Patricia, and Robillard Jane A, eds. The future of serials: Proceedings of the North American Serials Interest Group, Inc. 5th Annual Conference, June 2-5, 1990, Brock University, St. Catherines, Ontario. New York: Haworth Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "North American Vaccine Inc"

1

Hall, E. "Evaluation of SKC Inc. Dust Detective." In 11th US/North American Mine Ventilation Symposium 2006, 175–78. Taylor & Francis, 2006. http://dx.doi.org/10.1201/9781439833391.ch26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Feminism, Inc.: Globalization and North American Feminist Theologies." In The Oxford Handbook of Feminist Theology. Oxford University Press, 2011. http://dx.doi.org/10.1093/oxfordhb/9780199273881.003.0016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Song, Melodie Yun-Ju, and Julia Abelson. "Public Engagement and Policy Entrepreneurship on Social Media in the Time of Anti-Vaccination Movements." In Handbook of Research on Citizen Engagement and Public Participation in the Era of New Media, 38–56. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-1081-9.ch003.

Full text
Abstract:
North America has experienced a resurgence of measles outbreak due to an unprecedentedly low Mumps-Measles and Rubella vaccination coverage rates facilitated by the anti-vaccination movement. The objective of this chapter is to explore the new online public space and public discourse using Web 2.0 in the public health arena to answer the question ‘What is driving public acceptance of or hesitancy towards the MMR vaccine?' More specifically, typologies of online public engagement will be examined using MMR vaccine hesitancy as a case study to illustrate the different approaches used by pro- and anti-vaccine groups to inform, consult with and engage the public on a public health issue that has been the subject of long-standing public debate and confusion. This chapter provides an overview of the cyclical discourse of anti-vaccination movements. The authors hypothesize that anti-vaccination, vaccine hesitant, and pro-vaccination representations on the online public sphere is reflective of competing values (e.g., modernism, post-modernism) in contemporary society.
APA, Harvard, Vancouver, ISO, and other styles
4

Frost, Tony S. ""Interstitial opportunities" and the paradox of country risk: The case ofSiam Canadian Foods, Inc." In North American Firms in East Asia, edited by Paul Beamish. Toronto: University of Toronto Press, 1999. http://dx.doi.org/10.3138/9781442677777-008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McMahon, Suzanne, Miriam W. Palm, and Pamela S. Dunn. "Introduction." In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 1. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McCarty, Willard. "A Potency of Life: Scholarship in an Electronic Age." In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 79–97. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schmidt, Karen A. "Professionals or Professionless, Information Engineers or???" In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 99–107. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brown, Gary J. "From Past Imperfects to Future Perfects." In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 109–21. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bovenschulte, Robert, Maria L. Lebron, and Michele Crump. "New Strategies for Publishing." In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 123–26. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Meyers, Barbara. "A History of Journal Price Studies." In If We Build It: Scholarly Communications and Networking Technologies: Proceedings of the North American Serials Interest Group, Inc., 127–28. CRC Press, 2020. http://dx.doi.org/10.1201/9781003075271-17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "North American Vaccine Inc"

1

Lakowski, Leo, Russ Anderson, Ron Richter, Marcel D. Berz, Michael L. Britt, and John F. La Fond. "Power Generation and Superheater Upgrade Project at the Burnaby MSW Plant." In 11th North American Waste-to-Energy Conference. ASMEDC, 2003. http://dx.doi.org/10.1115/nawtec11-1666.

Full text
Abstract:
Montenay Inc. operates a municipal solid waste (MSW) incinerator plant located in Burnaby, British Columbia. The facility operates three essentially identical boilers that were designed to generate slightly superheated steam at 248°C (478°F) and 3,140 kPa (455 psig). The plant was originally sized to supply process steam for export to an adjacent industrial plant. The fraction of steam that was exported decreased in recent years to about 35% of the production with the remainder being condensed. This has caused Montenay Inc. to initiate a power generation project with the goal to improve the plants energy efficiency and generate additional revenues by purchasing and operating a steam turbine generator. A superheater upgrade was required to raise the final steam temperature to a level that was suitable for use in an efficient steam turbine-generator. Jansen Combustion and Boiler Technologies Inc. (JANSEN) was contracted to perform the process and design engineering for the required boiler modifications. The project work included defining target process conditions, deriving conceptual design options, sizing the new superheater, deciding on material selection, preparing equipment specifications, and supplying the fabrication and installation drawings. The boiler modifications has been implemented in all three units in spring 2003. Power production will start in early summer 2003.
APA, Harvard, Vancouver, ISO, and other styles
2

White, Thomas M., Donald J. Castro, and Robert Hauser. "Pinellas County Resource Recovery Facility Capital Replacement Project: One Year of Improved MSW Throughput and Electrical Generation." In 13th Annual North American Waste-to-Energy Conference. ASMEDC, 2005. http://dx.doi.org/10.1115/nawtec13-3163.

Full text
Abstract:
In May of 2003, the 3,150 TPD Pinellas County Resource Recovery Facility (PCRRF), the largest waste-to-energy plant in the United States, reached its 20-year milestone. The PCRRF is located in St. Petersburg, Florida, on a 705 acre (1.1 square mile) site owned by Pinellas County and known as “Bridgeway Acres”. The PCRRF has been owned by Pinellas County, operated by Wheelabrator Pinellas, Inc. (WPI) and monitored by HDR Engineering, Inc. since its inception. In addition to the PCRRF, the County operates both Class I and Class III landfills on the site.
APA, Harvard, Vancouver, ISO, and other styles
3

Taam, Damon M. K., and Chuck Conklin. "Supplemental Pit Fire Control Deluge System: Spokane Regional Waste to Energy Facility." In 17th Annual North American Waste-to-Energy Conference. ASMEDC, 2009. http://dx.doi.org/10.1115/nawtec17-2338.

Full text
Abstract:
After sixteen years of operation, it became apparent that the pit fire protection system installed during construction of the Spokane Regional Waste to Energy (WTE) Facility (1989–1991) was inadequate. A risk analysis was performed by Creighton Engineering Inc., a fire protection consulting firm, hired by the Spokane Regional Solid Waste System (Regional System) and Wheelabrator Spokane Inc. With input from Spokane County Fire District 10 and the City of Spokane Fire Department, a replacement supplemental fire protection system was designed and ultimately installed. This paper will describe the problems with the once state of the art fire system and the planning, design and installation of the new system.
APA, Harvard, Vancouver, ISO, and other styles
4

Richter, Ron. "2003 Upgrades at the GVRD Waste-to-Energy Facility." In 12th Annual North American Waste-to-Energy Conference. ASMEDC, 2004. http://dx.doi.org/10.1115/nawtec12-2203.

Full text
Abstract:
Montenay Inc. has operated the Greater Vancouver Regional District’s (GVRD) Waste-to-Energy Facility since it began commercial operation in 1988. The facility has a throughput of 720 tonnes (800 tons) per day in three lines. It utilizes Martin grate technology and dry lime injection with a reverse pulse jet fabric filter. The original facility design did not include a steam turbogenerator for energy recovery. The facility produced process steam at near saturation temperature to supply a recycle paper mill. The aging mill has reduced the fraction of steam used in recent years. This caused the GVRD and Montenay Inc. to cooperate in a major facility upgrade that began in 2001 and was completed in August of 2003. The complete project includes a turbogenerator, major boiler improvements and modernization of the boiler controls, while continuing to service the recycle paper mill.
APA, Harvard, Vancouver, ISO, and other styles
5

Asada, Vicki. "Comprehensive Power Engineer Training Increases Safety, Production and Plant Peformance at Montenay Inc., British Columbia, Canada: A Case Study." In 11th North American Waste-to-Energy Conference. ASMEDC, 2003. http://dx.doi.org/10.1115/nawtec11-1684.

Full text
Abstract:
Disastrous boiler and pressure vessel incidents result in loss of property and life. Most accidents are due to individual or human error, not equipment. It is important for plant supervisors and management to know how training has been implemented in a plant that has not had any accidents, and has also increased production and overall plant performance.
APA, Harvard, Vancouver, ISO, and other styles
6

Plavnik, Gene. "HTI’s Novel Deposit Removal Technology: Impulse Deposit Removal System (Abstract)." In 13th Annual North American Waste-to-Energy Conference. ASMEDC, 2005. http://dx.doi.org/10.1115/nawtec13-3144.

Full text
Abstract:
Heat Technologies, Inc. develops thermal systems based on the most advanced thermal techniques: pulsating heating and combustion, infrared heating, staged combustion, combined combustion, etc.. HTI is involved in the design and manufacturing of a new generation of equipment that deploy these techniques for various commercial and industrial processes. The utilization of aforementioned methods allows us to create compact, cost efficient, low in maintenance, and simple in operation equipment.
APA, Harvard, Vancouver, ISO, and other styles
7

Tsui, Tien-I., and Nathan B. Rich. "Air Pollution Control System Retrofit Experience at Wasatch Energy Systems." In 10th Annual North American Waste-to-Energy Conference. ASMEDC, 2002. http://dx.doi.org/10.1115/nawtec10-1005.

Full text
Abstract:
Wasatch Energy Systems owns and operates two (2) mass burn incinerators each rated at 210 tons/day in Layton, Utah. Each incinerator was equipped with a three field Electrostatic Precipitator (ESP) to control the particulate emissions. Dry sorbent (trona) was injected just upstream of the economizer to control acid gas emissions. The performance of the dry sorbent injection system was marginal. In anticipation of the upcoming EPA emission guidelines, 40 CFR Part 60, Subpart BBBB, Emission Guidelines for existing small municipal waste combustion units, Wasatch Energy Systems decided to update the existing APC systems several years ahead of the schedule. A request for proposal was released in October 1999 and eight proposals were received by the facility. AirPol Inc. of Parsippany, NJ was awarded a turnkey contract in June 2000 to add a dedicated Gas Suspension Absorber (FLS miljo Inc GSA) upstream of each existing ESP. A common lime slurry storage and preparation system, carbon storage and delivery system, ash conveying system, MCC, and control system were also provided under the contract. The new APC system was commissioned and put into service in September, 2001. Initial stack testing was conducted in October 2001 to evaluate system performance. Compliance stack testing was conducted for the Utah Division of Air Quality in November 2001. Results of testing demonstrate that particulate, metals, acid gas and dioxin/furan emissions from the retrofit facility are substantially lower than required under, now final, 40 CFR Part 60, Subpart BBBB – Class 1 Emission Limits for Existing Small Municipal Waste Combustion Units. This paper discusses the retrofit system design and performance.
APA, Harvard, Vancouver, ISO, and other styles
8

Castro, Donald J., and Lindsey J. Sampson. "The Lee County WTE Expansion Project: Building a New WTE Unit in the 21st Century." In 15th Annual North American Waste-to-Energy Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/nawtec15-3207.

Full text
Abstract:
The Lee County Expansion Project is a 636 ton per day Municipal Waste Combustor (MWC) in late stages of construction/startup, located in Ft. Myers, FL. The new unit complements the existing 1200 ton per day two-unit facility owned by the County and operated by Covanta Lee, Inc., which has been in service since 1994. The new unit is the first MWC permitted and constructed under the EPA’s New Source Performance Standards (NSPS) since they were promulgated in the 1990’s. This paper will describe the basic contractual arrangements, permitting, design and construction features, and overall costs for the expansion project.
APA, Harvard, Vancouver, ISO, and other styles
9

McCoy, Christine. "Fishing for Energy Partnership Cleans up Marine Debris Pollution and Promotes Benefits of Recycling and Energy-From-Waste." In 18th Annual North American Waste-to-Energy Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/nawtec18-3523.

Full text
Abstract:
Fishing for Energy (FfE) is a partnership of Covanta Energy Corporation, the National Fish and Wildlife Foundation (NFWF), the National Oceanic and Atmospheric Administration’s (NOAA) Marine Debris Program, and Schnitzer Steel Industries, Inc. The purpose of the FfE partnership is to provide fishermen with a no-cost disposal option for old or derelict fishing gear and to convert it into clean, renewable energy, using state-of-the-art Energy-from-Waste technology. To date, nearly 270 tons of gear has been collected, metals are recovered for recycling, and the rest has generated approximately 330 MWh of electricity.
APA, Harvard, Vancouver, ISO, and other styles
10

Amador, Pedro, and George Lai. "Application of Unifuse Overlay Tubes in the Convection Section of Waste-to-Energy Boilers." In 11th North American Waste-to-Energy Conference. ASMEDC, 2003. http://dx.doi.org/10.1115/nawtec11-1673.

Full text
Abstract:
The modern weld overlay applied by automatic gas-metal-arc welding (GMAW) process using Ni-Cr-Mo-Nb alloy 625 has been extremely successful in providing corrosion and erosion/corrosion protection for the waterwalls of waste-to-energy (WTE) boilers for over a decade. Without alloy 625 weld overlay protection, the carbon steel waterwall of a waste-to-energy boiler would be corroded through in a matter of months. The overlaid waterwalls for numerous WTE boilers have shown excellent performance results with services up to 10 years or more. Welding Services Inc. has developed a patented process for manufacturing weld overlay bimetallic tubes involving GMAW/GTAW process. Unifuse® 625 overlay tubing with carbon steel substrate has been successfully used as screen tubes, superheater tubes and generating banks in the convection section. The overlay tubes have successfully replaced such corrosion protection methods as stainless steel tube shields and refractories.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'North American Vaccine Inc' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography